Milford Funds Ltd. Acquires Shares of 132,628 Elevance Health, Inc. $ELV

Milford Funds Ltd. acquired a new stake in shares of Elevance Health, Inc. (NYSE:ELV) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 132,628 shares of the company’s stock, valued at approximately $46,493,000.

Several other institutional investors have also added to or reduced their stakes in the company. Rossby Financial LCC increased its holdings in shares of Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after buying an additional 44 shares in the last quarter. J.Safra Asset Management Corp acquired a new position in shares of Elevance Health during the fourth quarter worth $32,000. ORG Partners LLC increased its holdings in shares of Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after buying an additional 59 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in shares of Elevance Health during the fourth quarter worth $38,000. Finally, Dorato Capital Management acquired a new position in shares of Elevance Health during the fourth quarter worth $41,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ELV. Sanford C. Bernstein upped their price target on shares of Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a report on Friday, April 24th. Truist Financial upped their price target on shares of Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Citigroup upgraded shares of Elevance Health to a “buy” rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. raised their target price on Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. Finally, The Goldman Sachs Group raised their target price on Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and an average price target of $416.11.

Elevance Health Price Performance

ELV stock opened at $403.74 on Friday. The stock has a market capitalization of $87.68 billion, a PE ratio of 17.17, a price-to-earnings-growth ratio of 2.26 and a beta of 0.67. The company’s 50-day moving average is $366.62 and its 200-day moving average is $344.86. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $426.98.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities research analysts expect that Elevance Health, Inc. will post 26.93 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be given a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio is 29.26%.

Insider Activity

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This represents a 1.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.34% of the stock is owned by company insiders.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.